Propanc Biopharma, Inc. (PPCB) stock: key figures, P/E, revenue and dividend

Health Care · Australia · ISIN US74346N8002

Price
1.92 USD
Market cap
1.98 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-200.63 %
Return on assets (ROA)
-147.60 %

Propanc Biopharma, Inc. financials

Fiscal year20252026
Operating income-57.28 m USD-18.19 m USD
EBIT-58.36 m USD-18.43 m USD
Net income-58.92 m USD-18.86 m USD
Diluted EPS – continuing operations-14.85 USD-17.62 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.